Epidemiological studies strongly indicate that diabetes mellitus (DM) is an independent risk factor for both mortality and morbidity following myocardial infarction (MI), especially since post-MI left ventricular function is significantly worse in DM patients. However, what is lacking is a plausible relationship between diabetes and any of the known regulators of cardiomyocyte apoptosis known to play a significant role in the post-MI cardiac dysfunction. Our group has demonstrated that down-regulation of phosphodiesterase 3A (PDE3A) is associated with apoptosis and induction of inducible cAMP early repressor (ICER), a proapoptotic transcriptional repressor, providing a mechanistic framework for how angiotensin II (Ang II) regulates myocyte apoptosis. We also showed that ERK5 activation induced by cardiac specific overexpression of CA- MEK51 (constitutively active form of MEK51) in transgenic mice (Tg) inhibited ICER induction and myocyte apoptosis in DM mice after myocardial infarction (DM + MI), but the mechanism between ERK5 and ICER reduction remains unknown. Our preliminary data show that extracellular signal regulated protein kinase 5 (ERK5) and the chaperone-dependent E3 ubiquitin ligase CHIP (carboxyl terminus of Hsp70-interacting protein) are important in regulating heart damage after myocardial infarction in diabetes. ERK5 activation has a strong cardio-protective effect via inhibition of cardiomyocyte apoptosis. Moreover, ICER is ubiquitinated and degraded by CHIP and ERK5 activation enhances CHIP ubiquitin ligase activity, subsequent ICER and FoxO1 degradation, and inhibits both cardiomyocyte apoptosis and autophagy. Since CHIP knockout mice (KO) showed increased myocyte apoptosis and autophagy after pressure overlaod, our working hypothesis is that ERK5-mediated Ub ligase CHIP activation is a key modulator of ICER and FoxO1 protein degradation and protects cardiomyocytes from both apoptosis and autophagy after MI in DM. Activation of CHIP-mediated ubiquitination is not the """"""""only"""""""" downstream target of ERK5 activation, and there are several downstream molecules affected by ERK5 likely to impact MI injury. In this resubmission, we added a study on peroxisome proliferator-activated receptor (PPAR) 4 since ERK5 regulates PPAR4 transactivation in a CHIP-independent manner providing us with a platform to study CHIP-dependent vs. independent signaling in ERK5-mediated cardio-protection. Understanding the role and molecular mechanisms of ERK5-CHIP-mediated ICER and FoxO1 degradation and subsequent cardio-protection should provide insight into the reasons for poor cardiac recovery after MI in DM and possibly reveal a novel therapeutic target. The significance lies in the novel hypothesis on the role of the Ub-ligase CHIP in regulating both apoptosis and autophagy, and the proposed mechanistic study of a highly clinically relevant problem.

Public Health Relevance

The key role of cell death in cardiovascular disease and diabetes has become increasingly evident. At the basic science level understanding the specific signaling events involved in these mechanisms is a key issue that will be addressed here by biochemistry, cell biology, and in vivo transgenic mice. These studies should provide insight into mechanisms by which hyperglycemia promotes myocyte death and potentially facilitate development of new therapeutic approaches to limit cardiac dysfunction after myocardial infarction in patients with DM.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
7R01HL108551-05
Application #
8889329
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Wong, Renee P
Project Start
2011-08-15
Project End
2015-05-31
Budget Start
2014-08-02
Budget End
2015-05-31
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Anesthesiology
Type
Hospitals
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77030
Ko, Kyung Ae; Fujiwara, Keigi; Krishnan, Sunil et al. (2017) En Face Preparation of Mouse Blood Vessels. J Vis Exp :
Le, Nhat-Tu; Martin, James F; Fujiwara, Keigi et al. (2017) Sub-cellular localization specific SUMOylation in the heart. Biochim Biophys Acta Mol Basis Dis 1863:2041-2055
Chang, Eugene; Abe, Jun-Ichi (2016) Kinase-SUMO networks in diabetes-mediated cardiovascular disease. Metabolism 65:623-33
Abe, Jun-Ichi; Martin, James F; Yeh, Edward T H (2016) The Future of Onco-Cardiology: We Are Not Just ""Side Effect Hunters"". Circ Res 119:896-9
Abe, Jun-Ichi; Morrell, Craig (2016) Pyroptosis as a Regulated Form of Necrosis: PI+/Annexin V-/High Caspase 1/Low Caspase 9 Activity in Cells = Pyroptosis? Circ Res 118:1457-60
Abe, Jun-Ichi (2016) Multiple Functions of Protein Inhibitor of Activated STAT1 in Regulating Endothelial Cell Proliferation and Inflammation. Arterioscler Thromb Vasc Biol 36:1717-9
Chu, Uyen B; Duellman, Tyler; Weaver, Sara J et al. (2015) Endothelial protective genes induced by statin are mimicked by ERK5 activation as triggered by a drug combination of FTI-277 and GGTI-298. Biochim Biophys Acta 1850:1415-25
Cameron, Scott J; Ture, Sara K; Mickelsen, Deanne et al. (2015) Platelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct Expansion. Circulation 132:47-58
Abe, Jun-ichi; Berk, Bradford C (2014) Novel mechanisms of endothelial mechanotransduction. Arterioscler Thromb Vasc Biol 34:2378-86
Le, Nhat-Tu; Takei, Yuichiro; Izawa-Ishizawa, Yuki et al. (2014) Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents. J Immunol 193:3803-15

Showing the most recent 10 out of 22 publications